<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Turpin SM</dc:creator>
  <dc:creator>Nicholls HT</dc:creator>
  <dc:creator>Willmes DM</dc:creator>
  <dc:creator>Mourier A</dc:creator>
  <dc:creator>Brodesser S</dc:creator>
  <dc:creator>Wunderlich CM</dc:creator>
  <dc:creator>Mauer J</dc:creator>
  <dc:creator>Xu E</dc:creator>
  <dc:creator>Hammerschmidt P</dc:creator>
  <dc:creator>Brönneke HS</dc:creator>
  <dc:creator>Trifunovic A</dc:creator>
  <dc:creator>LoSasso G</dc:creator>
  <dc:creator>Wunderlich FT</dc:creator>
  <dc:creator>Kornfeld JW</dc:creator>
  <dc:creator>Blüher M</dc:creator>
  <dc:creator>Krönke M</dc:creator>
  <dc:creator>Brüning JC</dc:creator>
  <dc:date>2014</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Ceramides increase during obesity and promote insulin resistance. Ceramides vary in acyl-chain lengths from C14:0 to C30:0 and are synthesized by six ceramide synthase enzymes (CerS1-6). It remains unresolved whether obesity-associated alterations of specific CerSs and their defined acyl-chain length ceramides contribute to the manifestation of metabolic diseases. Here we reveal that CERS6 mRNA expression and C16:0 ceramides are elevated in adipose tissue of obese humans, and increased CERS6 expression correlates with insulin resistance. Conversely, CerS6-deficient (CerS6(Δ/Δ)) mice exhibit reduced C16:0 ceramides and are protected from high-fat-diet-induced obesity and glucose intolerance. CerS6 deletion increases energy expenditure and improves glucose tolerance, not only in CerS6(Δ/Δ) mice, but also in brown adipose tissue- (CerS6(ΔBAT)) and liver-specific (CerS6(ΔLIVER)) CerS6 knockout mice. CerS6 deficiency increases lipid utilization in BAT and liver. These experiments highlight CerS6 inhibition as a specific approach for the treatment of obesity and type 2 diabetes mellitus, circumventing the side effects of global ceramide synthesis inhibition.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/97175</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cmet.2014.08.002</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/25295788</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Cell metabolism. - 2014</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adipose Tissue, Brown</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Body Mass Index</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Ceramides</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Diet, High-Fat</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Glucose Intolerance</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Lipid Peroxidation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Liver</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Mice</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Mice, Inbred C57BL</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Mice, Knockout</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Mice, Transgenic</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Obesity</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">PPAR gamma</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Sphingosine N-Acyltransferase</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Weight Gain</dc:subject>
  <dc:title xmlns:ns20="xml" ns20:lang="en">Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
